Free Trial

Traws Pharma (TRAW) Stock Price, News & Analysis

-0.01 (-1.59%)
(As of 05/24/2024 ET)
Today's Range
50-Day Range
52-Week Range
42,637 shs
Average Volume
46,649 shs
Market Capitalization
$15.70 million
P/E Ratio
Dividend Yield
Price Target

About Traws Pharma

Traws Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for patients with check point inhibitor (CPI) resistant K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China; with SymBio Pharmaceuticals Limited for the development and commercialization of rigosertib in Japan and Korea; and Pint License Agreement to develop and commercialize any pharmaceutical product containing rigosertib in all uses of rigosertib in humans in Latin American countries. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

TRAW Stock Price History

TRAW Stock News Headlines

No headlines for this company have been tracked by
Receive TRAW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Traws Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$0.24 per share


Free Float
Market Cap
$15.70 million
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Steven M. Fruchtman M.D. (Age 73)
    President & Chief Scientific Officer of Oncology
    Comp: $907.86k
  • Mr. Mark Patrick Guerin CPA (Age 55)
    Chief Financial Officer
    Comp: $629.27k
  • Dr. Iain D. Dukes DPHIL (Age 66)
    M.A., Ph.D., Executive Chairman
  • Dr. Werner Cautreels Ph.D. (Age 72)
    CEO & Director
  • Dr. Nikolay Savchuk Ph.D. (Age 55)
    COO & Director
  • Dr. Victor Moyo M.D.
    Chief Medical Officer
  • Robert Redfield M.D.
    Acting Chief Medical Officer
  • Charles David Pauza Ph.D.
    Chief Scientific Officer of Virology

TRAW Stock Analysis - Frequently Asked Questions

How have TRAW shares performed in 2024?

Traws Pharma's stock was trading at $0.8081 on January 1st, 2024. Since then, TRAW stock has decreased by 23.2% and is now trading at $0.6207.
View the best growth stocks for 2024 here

When is Traws Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024.
View our TRAW earnings forecast

How were Traws Pharma's earnings last quarter?

Traws Pharma, Inc. (NASDAQ:TRAW) issued its quarterly earnings results on Wednesday, May, 15th. The company reported ($0.24) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.24). The firm had revenue of $0.06 million for the quarter, compared to analyst estimates of $0.06 million. Traws Pharma had a negative net margin of 8,033.63% and a negative trailing twelve-month return on equity of 144.95%.

How do I buy shares of Traws Pharma?

Shares of TRAW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TRAW) was last updated on 5/26/2024 by Staff

From Our Partners